 Hutchison China MediTech Limited Chi-Med or the Company NasdaqAIM: HCM today announces that it has entered into a definitive agreement for the sale of US100 million of shares at a price equivalent to US25.00 per American Depositary Share ADS via a private placement to General Atlantic, a leading global growth equity firm. This fundraise could increase to US200 million, through a warrant granted with a term of 18 months for a further US100 million in Chi-Med shares exercisable at a price per share equivalent to US30.00 per ADS, a 32.5 premium to the 30-day VWAP. Chi-Med is delivering on its strategic intention to become a global oncology business. 